References
- Unger T, Ganten D, Lang R E. Converting enzyme inhibitors: antihypertensive drugs with unexpected mechanisms. Trends pharmacol, Sci 1983; 4: 514–519
- Holaday J W. Cardiovascular effects of endogenous opiate systems Ann. Rev. Pharmacol. Toxicol 1983; 23: 541–594
- Schwartz J C. Metabolism of enkephalins and the inactivating neuropeptidase concept. Trends Neurosci 1983; 6: 45–48
- Baisset A, Laporte Y P. Montastruc, Contribution expérimental à l'étude des effets de l'uréthane sur les réflexes circulatoires généraux. Thérapie 1959; 14: 1053–1067
- Johansson B, Li C L, Olsson Y, Klatzo I. The effect of acute arterial hypertension on the blood-brain barrier to protein tracer. Acta Neuropath 1970; 16: 117–124
- Ercan Z S, Ilhan M, Turker R K. Alterations by captopril of pain reactions due to thermal stimulation of the mouse foot: interactions with morphine, naloxone and aprotinin, European. J. Pharmacol 1980; 63: 167–177
- Oktay S, Onur R, Mustafa I, Turker R K. Potentiation of the morphine-induced respiratory rate depression by captopril European. J. Pharmacol 1981; 70: 257–262
- Di Nicolantonio R, Hutchinson J S, Takada Y, Veroni M. captopril potentiates the vasodepressor action of Met-enkephalin in the anaesthetized rat Brit. J. Pharmacol 1983; 80: 405–408
- Laubie M, Schmitt H. Indication for central vagal endorphinic control of heart rate in dogs European. J. Pharmacol 1981; 63: 401–409